Opus Genetics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Opus Genetics, Inc. (IRD) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $380.94 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-21.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2020-10-29
- Opus Genetics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- Opus Genetics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $0.00.
- Opus Genetics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $0.00.
- Opus Genetics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $380.94K.
- Opus Genetics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $380.94K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $0.00 derived: sum of 3 quarters · filed 2020-10-29 | $380.94K 10-K · filed 2020-02-21 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $380.94K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $380.94K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $380.94K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |